PG(16:1(9Z)/18:3(6Z,9Z,12Z)) (BioDeep_00000031665)
human metabolite Endogenous
代谢物信息卡片
化学式: C40H71O10P (742.4784596)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCCCC=CCCCCCCCC(=O)OCC(COP(=O)(O)OCC(CO)O)OC(=O)CCCCC=CCC=CCC=CCCCCC
InChI: InChI=1S/C40H71O10P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-40(44)50-38(36-49-51(45,46)48-34-37(42)33-41)35-47-39(43)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h11,13-14,16-18,22,24,37-38,41-42H,3-10,12,15,19-21,23,25-36H2,1-2H3,(H,45,46)/b13-11-,16-14-,18-17-,24-22-/t37-,38+/m0/s1
描述信息
PG(16:1(9Z)/18:3(6Z,9Z,12Z)) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(16:1(9Z)/18:3(6Z,9Z,12Z)), in particular, consists of one chain of palmitoleic acid at the C-1 position and one chain of g-linolenic acid at the C-2 position. The palmitoleic acid moiety is derived from animal fats and vegetable oils, while the g-linolenic acid moiety is derived from animal fats. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PGs have a net charge of -1 at physiological pH and are found in high concentration in mitochondrial membranes and as components of pulmonary surfactant. PG also serves as a precursor for the synthesis of cardiolipin. PG is synthesized from CDP-diacylglycerol and glycerol-3-phosphate.
PG(16:1(9Z)/18:3(6Z,9Z,12Z)) is a phosphatidylglycerol. Phosphatidylglycerols consist of a glycerol 3-phosphate backbone esterified to either saturated or unsaturated fatty acids on carbons 1 and 2. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. PG(16:1(9Z)/18:3(6Z,9Z,12Z)), in particular, consists of one 9Z-hexadecenoyl chain to the C-1 atom, and one 6Z,9Z,12Z-octadecatrienoyl to the C-2 atom. In E. coli glycerophospholipid metabolism, phosphatidylglycerol is formed from phosphatidic acid (1,2-diacyl-sn-glycerol 3-phosphate) by a sequence of enzymatic reactions that proceeds via two intermediates, cytidine diphosphate diacylglycerol (CDP-diacylglycerol) and phosphatidylglycerophosphate (PGP, a phosphorylated phosphatidylglycerol). Phosphatidylglycerols, along with CDP-diacylglycerol, also serve as precursor molecules for the synthesis of cardiolipin, a phospholipid found in membranes.
同义名列表
19 个代谢物同义名
[(2S)-2,3-dihydroxypropoxy][(2R)-3-[(9Z)-hexadec-9-enoyloxy]-2-[(6Z,9Z,12Z)-octadeca-6,9,12-trienoyloxy]propoxy]phosphinic acid; (2S)-2,3-dihydroxypropoxy(2R)-3-[(9Z)-hexadec-9-enoyloxy]-2-[(6Z,9Z,12Z)-octadeca-6,9,12-trienoyloxy]propoxyphosphinic acid; 1-(9Z-Hexadecenoyl)-2-(6Z,9Z,12Z-octadecatrienoyl)-sn-glycero-3-phospho-(1-glycerol); 1-(9Z-Hexadecenoyl)-2-(6Z,9Z,12Z-octadecatrienoyl)-sn-glycero-3-phosphoglycerol; 1-Palmitoleoyl-2-gamma-linolenoyl-sn-glycero-3-phosphoglycerol; 1-Palmitoleoyl-2-g-linolenoyl-sn-glycero-3-phosphoglycerol; Phosphatidylglycerol(16:1n7/18:3n6); Phosphatidylglycerol(16:1W7/18:3W6); Phosphatidylglycerol(16:1/18:3); PG(16:1(9Z)/18:3(6Z,9Z,12Z)); Phosphatidylglycerol(34:4); GPG(16:1W7/18:3W6); GPG(16:1N7/18:3N6); PG(16:1W7/18:3W6); PG(16:1N7/18:3N6); GPG(16:1/18:3); PG(16:1/18:3); GPG(34:4); PG(34:4)
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:172816
- PubChem: 52926477
- HMDB: HMDB0010591
- foodb: FDB027741
- chemspider: 24768090
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
36 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(36)
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:0):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:0):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:0/20:0):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:0/20:3(5Z,8Z,11Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:0/20:3(8Z,11Z,14Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:0/20:4(5Z,8Z,11Z,14Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:0/20:4(8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/20:3(8Z,11Z,14Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
- Cardiolipin Biosynthesis CL(16:1(9Z)/18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)):
LPA(16:1(9Z)/0:0) + gamma-Linolenoyl-CoA ⟶ Coenzyme A + PA(16:1(9Z)/18:3(6Z,9Z,12Z))
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。